At present, there is an unmet need for novel oral drug formulations in inflammatory bowel disease (IBD) patients suffering from moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD). Key opinion leaders (KOLs) interviewed by GlobalData in Q2 2020 determine that sufferers would prefer an oral formulation over the current subcutaneously or intravenously delivered agents, due to less concern surrounding immunogenicity. Furthermore, the route of administration is simpler.
Last month, Bristol-Myers Squibb announced positive topline results from its pivotal Phase III TRUE NORTH trial in 1,012 patients evaluating Zeposia (ozanimod), an oral sphingosine1‐phosphate (S1P), in patients with moderate-to-severe UC. Read more here.